Chris Roukas

Chris Roukas

Auto-generated profile, based on publicly available information

Chris Roukas

Health Economics and Policy Research Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2021 in Trials
Verified
Journal Article
Open access
PDF file
CNChristine Norton
Christine Norton
JSJonathan Syred
Jonathan Syred
SKSally Kerry
Sally Kerry
MAMicol Artom
Micol Artom
LSLouise Sweeney
Louise Sweeney
RMRona Moss-Morris
Rona Moss-Morris
Background: Despite being in clinical remission, many people with inflammatory bowel disease (IBD) live with fatigue, chronic abdominal pain and bowel urgency or incontinence that limit their quality of life. We aim to test the effectiveness of an online self-management programme (BOOST), developed using cognitive behavioural principles and a theoretically informed logic model, and delivered with facilitator support. Primary research question: In people with IBD who report symptoms of fatigue, pain or urgency and express a desire for intervention, does a facilitator-supported tailored (to patient needs) online self-management programme for fatigue, pain and faecal urgency/incontinence improve IBD-related quality of life (measured using the UK-IBDQ) and global rating of symptom relief (0–10 scale) compared with care as usual? Methods: A pragmatic two-arm, parallel group randomised controlled trial (RCT), of a 12-session facilitator-supported online cognitive behavioural self-management programme versus care as usual to manage symptoms of fatigue, pain and faecal urgency/incontinence in IBD. Patients will be recruited through a previous large-scale survey of unselected people with inflammatory bowel disease. The UK Inflammatory Bowel Disease Questionnaire and global rating of symptom relief at 6 months are the co-primary outcomes, with multiple secondary outcomes measured also at 6 and 12 months post randomisation to assess maintenance. The RCT has an embedded pilot study, health economics evaluation and process evaluation. We will randomise 680 patients, 340 in each group. Demographic characteristics and outcome measures will be presented for both study groups at baseline. The UK-IBDQ and global rating of symptom relief at 6 and 12 months post randomisation will be compared between the study groups. Discussion: The BOOST online self-management programme for people with IBD-related symptoms of fatigue, pain and urgency has been designed to be easily scalable and implemented. If it is shown to improve patients’ quality of life, this trial will enable clinicians and patients to make informed management decisions. This is the first trial, to our knowledge, focused on multiple symptoms prioritised by both people with IBD and health professionals. Trial registration: ISRCTN71618461. Registered on 9 September 2019.

31 December 2024 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
AHAilsa Hart
Ailsa Hart
LMLaura Miller
Laura Miller
FBFionn Cléirigh Büttner
Fionn Cléirigh Büttner
THThomas Hamborg
Thomas Hamborg
SSSonia Saxena
Sonia Saxena
CNChristine Norton
Christine Norton
The co-existence of fatigue, pain and faecal incontinence in people with Inflammatory Bowel Disease (IBD) is unknown. We aimed to determine the presence of and relationship between these symptoms and patients’ desire for intervention. Adults with IBD in the UK, recruited from clinics, the national IBD-BioResource, a patient charity and social media sources, completed PROMIS validated patient-reported questionnaires to identify fatigue, pain and faecal incontinence, in addition to symptom severity and impact, disease activity, anxiety and depression questionnaires and questions about their desire for help with these symptoms. Statistical analysis used descriptive statistics to report presence of symptoms and Pearson correlation coefficients were calculated. Of 8486 responses, 54% reported faecal incontinence, 24% reported fatigue, and 21% reported pain; 10% reported all three symptoms in the past 7 days. Only 29% reported none of these symptoms. Fatigue and pain were moderately correlated (Pearson correlation coefficient 0.57); both fatigue and pain had a lower correlation with faecal incontinence (0.43 and 0.46 respectively). On a 0–10 scale for severity, participants scored fatigue highest, followed by incontinence then pain. For impact, participants scored incontinence highest, followed by fatigue then pain. 56% reported depression (27% with clinically relevant levels) and 49% reported anxiety (20% with clinically relevant levels); 23% had previously medically diagnosed mental health disorders. 56% of respondents “definitely” wanted help for fatigue; 53% for incontinence; 42% for pain; 29% “definitely” wanted help with all three symptoms. Factors associated with all three symptoms were Crohn’s disease (vs. ulcerative colitis), IBD activity, IBD Control score, anxiety, depression, and history of surgery (all p ≤ 0.0001). Fatigue, pain and incontinence are common in IBD and patients desire help for these symptoms, currently a substantial unmet need. Anxiety and depression are common, are underdiagnosed, and are independently associated with these symptoms.

25 July 2022 in Frontline Gastroenterology
Verified
Journal Article
Closed access
PDF file
CRChris Roukas
Chris Roukas
JSJonathan Syred
Jonathan Syred
VGVladimir Sergeevich Gordeev
Vladimir Sergeevich Gordeev
CNChristine Norton
Christine Norton
AHAilsa Hart
Ailsa Hart
BMBorislava Mihaylova
Borislava Mihaylova
Background and aims The increasing prevalence of inflammatory bowel disease (IBD) poses a substantial economic burden globally on health systems and societies. Validated instruments to collect data on healthcare and other service utilisation by patients with IBD are lacking. We developed a self-report patient questionnaire to capture key resource utilisation from health services, patient and societal perspectives. Methods The IBD Resource Use Questionnaire (IBD-RUQ), developed by a multidisciplinary team, including patients, comprises 102 items across the six categories of outpatient visits, diagnostics, medication, hospitalisations, employment and out-of-pocket expenses over the past three months. The test–retest reliability of the IBD-RUQ was studied by administering it twice among patients with IBD with a 2-week time gap. The intraclass correlation coefficients and the average cost from the healthcare, societal and patient perspectives, between test and retest assessments, overall and by service category, were summarised. Results The IBD-RUQ captures health service use, employment and out-of-pocket expenses. Of 55 patients who completed the first questionnaire, 48 completed the retest questionnaires and were included in the analyses. Test–retest reliability for categories of medications, diagnostics, specialist outpatient and inpatient services, and days off work due to IBD ranged from moderate to excellent; primary care visits showed more limited reliability. The annualised average self-reported health service, out-of-pocket and loss of productivity costs were £4844, £320 and £545 per patient, respectively. Conclusions The IBD-RUQ is a reliable and valid self-report measure of resource utilisation in adults with IBD and can be used to measure costs associated with IBD.

26 August 2022 in European Psychiatry
Verified
Journal Article
Open access
PDF file
YFY Feng
Y Feng
CRC Roukas
C Roukas
MRM Russo
M Russo
SRS Repišti
S Repišti
AKA Džubur Kulenović
A Džubur Kulenović
NJN Jovanović
N Jovanović
Background DIALOG+ is a digital psychosocial intervention aimed at making routine meetings between patients and clinicians therapeutically effective. This study aimed to evaluate the cost-effectiveness of implementing DIALOG+ treatment for patients with psychotic disorders in five low- and middle-income countries in Southeast Europe alongside a cluster randomised trial. Methods Resource use and quality of life data were collected alongside the multi-country cluster randomised trial of 468 participants with psychotic disorders. Due to COVID-19 interruptions of the trial's original 12-month intervention period, adjusted costs and quality-adjusted life years (QALYs) were estimated at the participant level using a mixed-effects model over the first 6 months only. We estimated the incremental cost-effectiveness ratio (ICER) with uncertainty presented using a cost-effectiveness plane and a cost-effectiveness acceptability curve. Seven sensitivity analyses were conducted to check the robustness of the findings. Results The average cost of delivering DIALOG+ was euro91.11 per participant. DIALOG+ was associated with an incremental health gain of 0.0032 QALYs (95% CI -0.0015, 0.0079), incremental costs of euro84.17 (95% CI -8.18, 176.52), and an estimated ICER of euro26,347.61. The probability of DIALOG+ being cost-effective against three times the weighted gross domestic product (GDP) per capita for the five participating countries was 18.9%. Conclusion Evidence from the cost-effectiveness analyses in this study suggested that DIALOG+ involved relatively low costs. However, it is not likely to be cost-effective in the five participating countries compared with standard care against a willingness-to-pay threshold of three times the weighted GDP per capita per QALY gained.

11 September 2025 in Frontline Gastroenterology
Verified
Journal Article
Closed access
PDF file
AUAdvait Upadhyaya
Advait Upadhyaya
RTRabia Topan
Rabia Topan
SPShraya Pandya
Shraya Pandya
SWSarah Williams
Sarah Williams
KFKonstantinos Fragkos
Konstantinos Fragkos
AFAsma Fikree
Asma Fikree
Background/objective Disorders of Gut–Brain interactions (DGBI), for example, Functional Dyspepsia (FD) or Irritable Bowel syndrome (IBS), are common in patients with hypermobile Ehlers-Danlos syndrome/hypermobile spectrum disorder (hEDS/HSD). DGBI is associated with significant healthcare use—how this applies to patients with coexisting hEDS/HSD is unknown. Design A cross-sectional study was performed. Patients recruited from tertiary neurogastroenterology clinics and from Ehlers-Danlos Support UK completed questionnaires, characterising their demographic, healthcare data and expenses, over 6 months (July 2021–January 2022) and their Rome IV diagnoses. National Health Service (NHS) unit costs were used. Healthcare use and costs were compared across and between DGBI and non-DGBI subgroups. Regression analysis was performed to determine predictors of costs. p<0.005 was considered significant. Results Median age of the 660 respondents was 39 (IQR: 29–50) years; 96.1% had a DGBI. 13.6% had IBS, 29.9% had FD, 32.1% had IBS and FD, 24.4% had neither. Patients with DGBI had high healthcare use and large healthcare costs; £3388.79/6 months, mostly attributed to consultations (36.4%) and admissions (22.7%). Costs per patient (pp) were at least double in any group with FD (£4026.53–£4297.30pp) compared with those without (£1372.49–£1979.36pp), p£20 000 pp/6 months). Predictors of rising costs were FD, non-gastrointestinal comorbidities, lower body mass index, positive avoidant/restrictive food intake disorders screen, having an altered diet, polypharmacy, visits to different healthcare professionals and tertiary neurogastroenterology recruitment. Conclusions It is imperative to develop cost-effective multidisciplinary services for hEDS/HSD patients with FD, particularly in the current fiscal climate, as they have significant healthcare use and costs.

1 August 2026 in Programme Grants for Applied Research
Verified
Journal Article
Open access
CNChristine Norton
Christine Norton
AHAilsa Hart
Ailsa Hart
RMRona Moss-Morris
Rona Moss-Morris
LMLaura Miller
Laura Miller
QAQasim Aziz
Qasim Aziz
VWVari Wileman
Vari Wileman
Background: Inflammatory bowel disease (IBD) adversely impacts the quality of life. Healthcare professionals target treatment at controlling gut inflammation. However, patients report troublesome symptoms of fatigue, abdominal pain and urgency or faecal incontinence in the absence of inflammation. Objectives: To address the symptoms of fatigue, pain and urgency/faecal incontinence in people living with inflammatory bowel disease. Research questions: Identifying the burden of symptoms: 1a. What proportion of people with inflammatory bowel disease have fatigue, pain or urgency/faecal incontinence and want help for them? 1b. Which symptoms could benefit from optimisation of medical treatment? Addressing symptoms: 2a. To develop and test a supported tailored online self-management programme (IBD-BOOST) for these symptoms in inflammatory bowel disease to improve the quality of life and reduce symptoms. 2b. Does better symptom control reduce healthcare and personal costs and is the intervention cost-effective? Design and methods: Qualitative interviews with patients and nurses. Questionnaire to identify the inter-relationship of symptoms and the desire for intervention. Feasibility study of a checklist and algorithm (‘Optimise’) to manage medically reversible causes of symptoms. Multicentre, two-arm, parallel-group, randomised controlled trial of the IBD-BOOST intervention with qualitative and quantitative process evaluation. Target population: 740 people with inflammatory bowel disease recruited from the questionnaire survey. Six months of access to IBD-BOOST was compared with care as usual. Setting and participants: United Kingdom inflammatory bowel disease clinics and online. Interventions: Randomised controlled trial – a 12-session online self-management IBD-BOOST intervention, developed jointly with patients. Main outcome measures: Primary outcomes for randomised controlled trial: United Kingdom Inflammatory Bowel Disease Questionnaire (inflammatory bowel disease-related quality of life) and Global Rating of Symptom Relief at 6 months. Cost-effectiveness of IBD-BOOST was assessed: incremental cost per quality-adjusted life-year 1 year following randomisation from healthcare service and societal perspectives. Results: Interviews: People with inflammatory bowel disease told us that they wanted help to self-manage their symptoms. Inflammatory bowel disease nurses wanted to be supportive but reported limited capacity to help. Survey: There were 8486 responses: 3281 men and 4883 women. In the previous week, 2550 (30%) reported fatigue; 1766 (21%) pain and 4565 (54%) reported faecal incontinence; 925 (10.9%) reported all three; 56% of all respondents ‘definitely’ wanted help for fatigue; 42% wanted help for pain; 53% wanted help for incontinence and 29% ‘definitely’ wanted help for all three symptoms. Feasibility study of the optimise checklist and algorithm: The 201/515 (39%) individuals reporting symptoms consented and 194/201 (97%) returned the symptom checklist; 157 (81%) returned a postal faecal calprotectin sample. The algorithm suggested at least one clinical test or intervention for fatigue, pain or incontinence in 67/157 (43%) participants, of whom 25 (37%) declined intervention for reasons unknown. Of those for whom clinical actions were indicated, 66% completed 3-month follow-up. Randomised controlled trial of the IBD-BOOST intervention: Participants ( N = 780) were randomised to the intervention ( n = 391) or care as usual ( n = 389). At 6 months, there were no statistically significant between-arm differences for United Kingdom Inflammatory Bowel Disease Questionnaire [mean difference = −1.67 (95% confidence interval = −4.17 to 0.83), p = 0.19] and Global Rating of Symptom Relief [mean difference = 0.44 (95% confidence interval = −0.56 to 1.43), p = 0.39]. Complier-averaged causal effects analysis demonstrated that participants who complied with the intervention reported better United Kingdom-Inflammatory Bowel Disease Questionnaire scores than ‘would-be’ compliers receiving care as usual ( p = 0.03). Subgroup analyses did not identify any statistically significant treatment effect modifiers; 57% completed four sessions or more. Serious adverse events were similar between groups. Process evaluation suggested high facilitator fidelity but low overall participant compliance with the programme. Cost-effectiveness of the IBD-BOOST intervention: Per participant cost for the development and delivery of intervention was £151.19. Allocation to inflammatory bowel disease-BOOST intervention resulted in additional 0.016 quality-adjusted life-years (95% confidence interval = 0.002 to 0.030) per participant over 12 months and cost savings of −£304.66 (−803.51; 194.18) for healthcare costs and −£39.48 (−388.09; 309.12) for out-of-pocket costs and time off work over months 3–6 and 9–12. Over the 12-month follow-up, there were cost savings of −£28,633 (95% confidence interval = −51,555 to 18,764) and −£33,568 (−64,421; 26,198) per quality-adjusted life-year gained with inflammatory bowel disease-BOOST from health services and societal perspectives, respectively. Limitations: Our samples were predominantly White and English-speaking. Conclusions: People with inflammatory bowel disease want help with their symptoms, but health professionals lack capacity. Over half of people with inflammatory bowel disease have faecal incontinence, and 1 in 10 have fatigue, pain and incontinence. Nearly a third want help for all three. Screening using a checklist and algorithm was feasible, and we identified around 40% who could benefit from optimisation of their medical treatment. Inflammatory bowel disease-BOOST had low compliance and did not improve disease-specific quality of life or Global Rating of Symptom Relief in inflammatory bowel disease patients with fatigue, pain and/or incontinence compared with care as usual, but it may help symptoms in people who comply with the programme. The economic evaluation indicated that the inflammatory bowel disease-BOOST intervention improves quality-adjusted life-years, and could be cost-effective, but economic results did not reach statistical significance. Future work: Research should explore targeting the intervention to specific subgroups within inflammatory bowel disease and improving adherence to digital interventions. Study registration: This study is registered as Optimising medical management ISRCTN15380317 and the RCT as ISRCTN71618461. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research Programme (NIHR award ref: RP-PG-0216-20001) and is published in full in Programme Grants for Applied Research ; Vol. 14, No. 19. See the NIHR Funding and Awards website for further award information.